deltatrials
Completed PHASE3 NCT00328380

Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety of Rifaximin for the Prevention of Travelers' Diarrhea in Subjects Traveling Outside the United States

Sponsor: Bausch Health Americas, Inc.

Conditions Diarrhea
Interventions Rifaximin
Updated 7 times since 2017 Last updated: Nov 21, 2019 Started: Dec 31, 2005 Primary completion: Dec 31, 2006 Completion: Sep 30, 2008

This PHASE3 trial investigates Diarrhea and is currently completed. Bausch Health Americas, Inc. leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jun 2019 — Dec 2019 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Jun 2019 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bausch Health Americas, Inc.
Data source: Bausch Health Americas, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States
  • • La Porte, United States
  • • South Miami, United States